Atai Beckley Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATAI research report →
Range $7.45 – $8
Price Chart
About the company
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada.
- CEO
- Srinivas G. Rao
- IPO
- 2021
- Employees
- 99
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on ATAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.73B
- P/E
- -2.53
- PEG
- 0.01
- P/S
- 609.40
- P/B
- 15.03
- EV/EBITDA
- -3.77
- Div Yield
- 91.84%
- Gross Margin
- 86.25%
- Op Margin
- -3274.31%
- Net Margin
- -14938.37%
- ROE
- -353.23%
- ROIC
- -61.29%
Latest fiscal year · YoY change
- Revenue
- $4.09M+1227.6%
- Gross Profit
- $3.08M+1964.8%
- Op Income
- $-99,761,000
- Net Income
- $-660,047,000-342.2%
- EPS
- $-2.91-212.9%
- OCF Growth
- -24.5%
- FCF Growth
- -25.5%
- 52W High
- $7.45
- 52W Low
- $3.27
- 50D MA
- $6.90
- 200D MA
- $4.74
- Beta
- 1.55
- RSI (14)
- 62
- Avg Volume
- 14.44M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Atai said Q3 progress was broad across the pipeline, with PCN-101 (R-ketamine) top-line Phase 2a data expected around year-end and cash runway into 2025.· November 10, 2022
- Q3 operating cash use was $28 million, in line with expectations.
- Atai ended Q3 with $304 million in cash and reiterated runway into 2025, helped by a Hercules facility of up to $175 million.
- PCN-101 Phase 2a in treatment-resistant depression is fully enrolled, with data expected around the end of the year.
- Management said the R-ketamine goal is an at-home, rapid-onset treatment with intermittent dosing and a therapeutic profile that supports unsupervised use.
- RL007 in CIAS is moving forward with Phase 2a/2b plans, and the company also highlighted positive initial Phase 1 results for GRX-917 and KUR-101.
Atai did not report revenue or EPS on this call. Stephen Bardin said Q3 operating use of cash was $28 million and was in line with expectations. The company ended Q3 with $304 million in cash, after drawing the initial $15 million on its Hercules facility, which can provide access to up to $175 million. Management reiterated that cash runway extends into 2025. Looking ahead, Atai expects top-line Phase 2a data for PCN-101 in R-ketamine around the end of this year, and plans to initiate the larger Phase 2b study for RL007 in CIAS still this year.
Florian Brand framed Atai as a broad mental-health platform with 8 drug development programs in the clinic and 4 enabling technologies. He emphasized that the company expects multiple efficacy readouts over the next 2 years to serve as value inflection points, with PCN-101 as the near-term catalyst. His tone was confident and focused on differentiation: for R-ketamine, he repeatedly stressed at-home administration, rapid onset, intermittent dosing, and a profile that can support unsupervised use.
Stephen Bardin highlighted a clean quarter from a cash perspective: Q3 operating use of cash was $28 million, in line with expectations. He also pointed to a strengthened balance sheet, noting $304 million in cash at quarter-end plus access to up to $175 million under the Hercules debt facility; Atai drew the initial $15 million in mid-August. He reiterated runway into 2025 and described the capital position as strong.
Most of the Q&A centered on how Atai is defining success for PCN-101, especially the tradeoff between efficacy and tolerability. Management said the target is a placebo-adjusted efficacy of about 5 points at hour 24 in Phase 2a, while also aiming for sedation/dissociation/hallucination levels that are comparable to placebo and meaningfully better than Spravato, so at-home use is feasible. They also discussed dose selection for RL007 and said the MCCB was chosen because it has FDA precedent in CIAS, while the VRFCAT measures cognition-related function through daily-living simulation.
The bullish case from this call is that Atai has multiple shots on goal, with a near-term PCN-101 readout that management sees as a potential major value inflection point. The company also said its balance sheet is strong, with cash and debt capacity supporting runway into 2025, which reduces financing pressure while the pipeline advances. Management sounded confident that several programs have already shown encouraging early signals, including GRX-917 and KUR-101.
The main risk is that the call was still highly dependent on future data, especially the PCN-101 Phase 2a readout, which management said could force a reassessment if single-dose efficacy is below what is clinically meaningful. The company is also pursuing demanding product goals for R-ketamine, including at-home use and a favorable sedation/dissociation profile, which may prove hard to achieve. On RL007, management acknowledged CIAS is a challenging indication with a high unmet need, and the program still needs larger-trial validation.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 54.3%
- Shares Outstanding
- 370.86M
- Float Shares
- 201.02M
of shares held by institutions
195 13F filers
Buy/sell ratio 10.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 25.57M | ▲ 18.74M |
| Deep Track Capital, LP | 14.42M | ▲ 2.42M |
| Vanguard Capital Management LLC | 11.75M | ▼ 14.15K |
| State Street Corp | 8.29M | ▲ 7.14M |
| Adage Capital Partners Gp, L.L.C. | 5.64M | 0 |
| Ubs Group AG | 4.42M | ▼ 3.00M |
| Vanguard Portfolio Management LLC | 4.11M | ▲ 4.11M |
| Morgan Stanley | 3.84M | ▼ 9.52K |
| Foresite Capital Management Vi LLC | 2.75M | 0 |
| Northern Trust Corp | 2.59M | ▲ 2.05M |
| Citadel Advisors LLC | 2.11M | ▲ 1.94M |
| Rtw Investments, LP | 2.00M | 0 |
Held by 12 ETFs
Biggest fund positions in ATAI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 25, 25 | Feilding-Mellen Cosmo | other | 10,000 |
| Nov 25, 25 | Feilding-Mellen Cosmo | sell | 40,400 |
| Nov 5, 25 | HERSHBERG ROBERT | other | 456,011 |
| Nov 5, 25 | HERSHBERG ROBERT | other | 103,000 |
| Nov 5, 25 | HERSHBERG ROBERT | other | 97,716 |
| Nov 5, 25 | HERSHBERG ROBERT | other | 62,394 |
| Nov 5, 25 | Feilding-Mellen Cosmo | other | 7,702,990 |
| Nov 5, 25 | Feilding-Mellen Cosmo | other | 103,000 |
| Nov 5, 25 | Feilding-Mellen Cosmo | other | 40,400 |
| Nov 4, 25 | Braunstein Scott | other | 56,818 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATAI coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ATAI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
zacks.com · Sep 10
Lilly Builds Neuroscience into a New Long-Term Growth Driver
zacks.com · Sep 8
Jim Cramer Isn't Sure If There's Upside In This Health Care Stock
benzinga.com · Sep 3
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
gurufocus.com · Aug 28
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
prnewswire.com · Aug 28
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
gurufocus.com · Aug 17
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
prnewswire.com · Aug 17
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
gurufocus.com · Aug 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
